THE ROLE OF HTA AGENCY IN DRUG REIMBURSEMENT DECISION-MAKING PROCESS IN POLAND (HTA IMPACT)

被引：2
|
作者：
Kolasa, K. [1 ]
机构：
[1] AstraZeneca, Sodertalje, Sweden
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74230-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A251 / A251
页数：1
相关论文
共 50 条
  • [31] Most important barriers and facilitators of HTA usage in decision-making in Europe
    Cheung, K. L.
    Evers, S. M. A. A.
    De Vries, H.
    Levy, P.
    Pokhrel, S.
    Jones, T.
    Danner, M.
    Wentlandt, J.
    Knufinke, L.
    Mayer, S.
    Hiligsmann, M.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (03) : 297 - 304
  • [32] Advancing HTA in Latin America: The Policy Process of Setting up an HTA Agency in Colombia
    Castro, Hector E.
    GLOBAL POLICY, 2017, 8 : 97 - 102
  • [33] TOWARDS MORE TRANSPARENT HTA PROCESS IN POLAND - NEW POLISH HTA METHODOLOGICAL GUIDELINES
    Lach, K.
    Dziwisz, M.
    Remuzat, C.
    Toumi, M.
    VALUE IN HEALTH, 2016, 19 (07) : A492 - A492
  • [34] COMPARING THE VALUE OF DIFFERENT HTA DECISION MAKING PROCESS: EVALUATING THE EVALUATORS
    Johannesen, K. M.
    Claxton, K.
    Sculpher, M. J.
    Wailoo, A. J.
    VALUE IN HEALTH, 2013, 16 (07) : A489 - A489
  • [35] Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on Polish HTA agency
    Mela, Aneta
    Tysarowski, Andrzej
    Rdzanek, Elzbieta
    Blicharski, Tomasz
    Jaroszynski, Janusz
    Furtak-Niczyporuk, Marzena
    Jahnz-Rozyk, Karina
    Niewada, Maciej
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 265 - 273
  • [36] BENCHMARKING THE IMPACT OF HTA ON NEW MEDICINES DEVELOPMENT AND COVERAGE DECISION MAKING
    Wang, T.
    VALUE IN HEALTH, 2014, 17 (07) : A798 - A798
  • [37] Expected value of information and decision making in HTA
    Eckermann, Simon
    Willan, Andrew R.
    HEALTH ECONOMICS, 2007, 16 (02) : 195 - 209
  • [38] THE USE OF MCDA IN HTA DECISION MAKING IN BULGARIA
    Sidjimova, D. A.
    Stoimenova, A.
    Benisheva, T.
    Borisov, B.
    Trendafilova, P.
    VALUE IN HEALTH, 2017, 20 (09) : A698 - A698
  • [39] HTA decision-making for drugs for rare diseases: comparison of processes across countries
    Tania Stafinski
    Judith Glennie
    Andrea Young
    Devidas Menon
    Orphanet Journal of Rare Diseases, 17
  • [40] DOES REAL-WORLD EVIDENCE PLAY A ROLE IN DECISION-MAKING BY HTA BODIES FOR MEDICAL TECHNOLOGIES?
    Hartley, L.
    Gildea, L.
    Mordin, M.
    Long, J.
    D'Souza, V
    Kinderas, M.
    Ling, C.
    Warttig, S.
    VALUE IN HEALTH, 2023, 26 (12) : S434 - S435
12345